Skip to main content

Table 3 Association of risk factors with VTE occurrence

From: Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study

 

The total follow-up period

The first six months

VTE

DVE

PE

VTE

DVE

PE

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Unadjusted HR

 Age per 5 years

1.244 (1.187–1.303)

< 0.001

1.205 (1.128–1.287)

< 0.001

1.294 (1.216–1.378)

< 0.001

1.175 (1.096–1.258)

< 0.001

1.151 (1.038–1.275)

0.008

1.177 (1.076–1.287)

< 0.001

 Low SES a

1.547 (1.005–2.381)

0.048

1.413 (0.747–2.675)

0.288

1.756 (1.02–3.023)

0.042

0.889 (0.393–2.011)

0.778

0.325 (0.045–2.338)

0.264

1.27 (0.515–3.127)

0.604

 CCI

1.159 (1.112–1.208)

< 0.001

1.148 (1.081–1.22)

< 0.001

1.164 (1.102–1.229)

< 0.001

1.073 (0.999–1.153)

0.054

1.051 (0.938–1.176)

0.392

1.078 (0.983–1.182)

0.603

 Year of endometrial cancer diagnosis

1.116 (1.069–1.165)

< 0.001

1.118 (1.051–1.19)

< 0.001

1.109 (1.048–1.174)

< 0.001

1.138 (1.071–1.209)

< 0.001

1.145 (1.045–1.254)

0.004

1.129 (1.045–1.221)

0.002

 Types of primary treatment b,c

  Surgery d

0.91 (0.696–1.189)

0.489

0.995 (0.677–1.463)

0.979

0.857 (0.603–1.219)

0.391

1.03 (0.691–1.535)

0.885

1.137 (0.618–2.093)

0.68

1.034 (0.613–1.747)

0.899

  Radiotherapy

0.79 (0.343–1.818)

0.579

1.11 (0.393–3.134)

0.843

0.676 (0.209–2.182)

0.512

1.26 (0.446–3.576)

0.661

2.259 (0.644–7.927)

0.203

1.087 (0.252–4.684)

0.911

  Chemotherapy

2.614 (1.554–4.395)

< 0.001

2.234 (0.986–5.063)

0.054

2.934 (1.538–5.596)

0.001

2.956 (1.518–5.757)

0.001

1.756 (0.5–6.163)

0.379

3.827 (1.719–8.521)

0.001

  Hormone therapy

1.261 (0.83–1.915)

0.278

1.173 (0.628–2.192)

0.617

1.207 (0.693–2.101)

0.506

0 (0-Infinite)

0.991

0 (0-Infinite)

0.994

0 (0-Infinite)

0.991

Adjusted HR e

 Age per 5 years

1.231 (1.175–1.29)

< 0.001

1.191 (1.114–1.273)

< 0.001

1.279 (1.201–1.363)

< 0.001

1.147 (1.066–1.235)

< 0.001

1.125 (1.006–1.257)

0.038

1.148 (1.043–1.263)

0.005

 Low SES a

1.119 (0.723–1.734)

0.614

1.075 (0.564–2.052)

0.826

1.205 (0.694–2.094)

0.507

0.722 (0.317–1.646)

0.439

0.271 (0.037–1.966)

0.197

1.035 (0.416–2.578)

0.941

 CCI

1.121 (1.071–1.173)

< 0.001

1.125 (1.054–1.2)

< 0.001

1.112 (1.047–1.181)

< 0.001

1.057 (0.979–1.142)

0.156

1.056 (0.936–1.191)

0.374

1.052 (0.953–1.162)

0.316

 Year of endometrial cancer diagnosis

1.112 (1.064–1.162)

< 0.001

1.116 (1.048–1.189)

0.001

1.101 (1.039–1.167)

0.001

1.124 (1.057–1.194)

< 0.001

1.141 (1.041–1.25)

0.005

1.11 (1.026–1.201)

0.009

 Types of primary treatment b,c

  Surgery d

1.081 (0.821–1.424)

0.579

1.166 (0.784–1.732)

0.448

1.033 (0.718–1.486)

0.862

1.111 (0.739–1.671)

0.614

1.202 (0.645–2.239)

0.563

1.122 (0.657–1.917)

0.672

  Radiotherapy

0.849 (0.368–1.957)

0.701

1.196 (0.423–3.382)

0.736

0.72 (0.223–2.33)

0.584

1.383 (0.487–3.927)

0.542

2.516 (0.714–8.866)

0.151

1.174 (0.272–5.076)

0.83

  Chemotherapy

2.334 (1.38–3.949)

0.002

1.944 (0.852–4.437)

0.114

2.742 (1.424–5.278)

0.003

2.532 (1.291–4.966)

0.007

1.452 (0.411–5.137)

0.563

3.366 (1.496–7.576)

0.003

  Hormone therapy

2.073 (1.356–3.17)

0.001

1.837 (0.973–3.469)

0.061

2.086 (1.19–3.657)

0.01

0 (0-Infinite)

0.991

0 (0-Infinite)

0.994

0 (0-Infinite)

0.994

  1. CCI Charlson comorbidity index; CI confidence interval; DVT deep vein thrombosis; HIRA health insurance review & assessment service; HR hazard ratio; SES socioeconomic status; PE pulmonary embolism; VTE venous thromboembolism
  2. a The reference was mid- or high- SES
  3. b Primary treatments refers to the first cancer treatments
  4. c) The reference was no treatment. In patients that received no treatment, the incidence of VTE after diagnosis of endometrial cancer was evaluated
  5. d Neoadjuvant chemotherapy followed by laparotomy or laparoscopy was considered as surgery
  6. e The data were adjusted for all risk factors (age per 5 years, SES, CCI, year of endometrial cancer diagnosis, and types of primary treatment)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us